COMP <GO>
DRS vs TMO // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Leonardo DRS Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: DRS 4
— TMO 10
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: DRS
LAST: $37.68 (-4.94%) • MKT CAP: $10.58B
options-implied-move
6.50%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
options-implied-move
6.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DRS VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DRS | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 23.80% | 41.00% | -17.20 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.20% | 9.30% | -0.10 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 23.2x | 30.4x | -7.20 | DRS | /valuation <GO> |
| Free Cash Flow Yield | 2.15% | 2.40% | -0.25 | TMO | /fcf-yield <GO> |
| Operating Margin | 9.50% | 17.40% | -7.90 | TMO | /operating-margins <GO> |
| Net Profit Margin | 7.60% | 15.10% | -7.50 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 12.80% | 3.90% | +8.90 | DRS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.59 | 4.50 | -0.91 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.50% | 6.70% | -0.20 | DRS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.6 | 59.1 | -2.54 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.94 | -0.05 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 36.3x | -4.30 | DRS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.58B | $262.22B | -$251.64B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DRS REV | TMO REV | DRS GROSS % | TMO GROSS % | DRS FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.65B | $44.56B | 23.8% | 44.0% | $227.0M | $6.29B |
| FY 2024 | $3.23B | $42.88B | 22.8% | 44.0% | $186.0M | $7.27B |
| FY 2023 | $2.83B | $42.86B | 44.0% | 44.0% | $77.8M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DRS // BETA 0.89
TMO // BETA 0.94